Sacubitril/ valsartan in patients with congenital heart disease: a systematic review and meta-analysis

29 August 2025 (07:00 - 18:00)

Organised by:

Sign in for access options

Sign in to view the resources

Sign in for access options

About the speaker

Doctor Despoina Ntiloudi

Tzaneio General Hospital of Piraeus, Pireas (Greece)

8 More presentations in this session

Presentation thumbnail

Dapagliflozin prevents fibrogenic activation in endocardial endothelial cells under altered flow

Ms J. Gaal (Boston, US) Doctor I. Friehs (Boston, US)

Abstract Slides Video

Presentation thumbnail

Sodium-glucose cotransporter 2 inhibitors for the treatment of single ventricle circulatory failure in adults with congenital heart disease

Doctor R. Neijenhuis (Leiden, NL)

Abstract Slides Video

Presentation thumbnail

Results of CHASM IN ACHD (peer CoacHing Adaptive Self-Management INterventions for young Adults with Congenital Heart Disease) study

Doctor R. Krasuski (Durham, US)

Abstract Slides Video

Presentation thumbnail

Sodium-glucose cotransporter-2 inhibitor use in children with left ventricular systolic dysfunction: a matched case-control analysis

Doctor D. Newland (Seattle, US)

Abstract Slides Video

Presentation thumbnail

Impact on adverse events of guideline-directed medical therapy for heart failure in patients with a systemic right ventricle

Doctor I. Altobelli (Naples, IT)

Abstract Slides Video

Access the full session

Session thumbnail

Adult congenital heart disease: medical treatment

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025

You may be interested in

Congress Presentation

Defining clinical worsening in adult patients with congenital heart disease and heart failure

Congress Session

Novel metrics to improve outcomes in congenital heart disease

Congress Session

Congenital heart disease

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources